Preliminary results of a clinical trial that involved the use of the CRISPR-Cas9 gene-editing show that the technique was safe to use on humans. More specifically, researchers at the University of Pennsylvania in Philadelphia collected immune cells from three people with cancer, and, through genome editing, gave those cells the ability to recognise a protein produced by some cancer cells. Upon being reintroduced into the patients' bodies, the cells did not cause significant side effects.
Regístrepor correo electrónico ahora para acciones semanales de promoción
100% free, Unsubscribe any time!Add 1: Room 605 6/F FA YUEN Commercial Building, 75-77 FA YUEN Street, Mongkok KL, HongKong Add 2: Room 405, Building E, MeiDu Building, Gong Shu District, Hangzhou City, Zhejiang Province, China
Whatsapp/Tel: +8618057156223 Tel: 0086 571 86729517 Tel en Hong Kong: 00852 66181601
Correo electrónico: [email protected]